Skip to main content
. 2018 Jun 14;10(6):200. doi: 10.3390/cancers10060200

Figure 1.

Figure 1

CD19 chimeric antigen receptor (CAR) transduced primary human CD8+ T cells (CTLs) kill CD19+ human non-Hodgkin’s lymphoma (NHL) cell lines. (A) The transduction efficiency of CD19CAR transduced lymphocytes was measured by fluorescence-activated cell sorting (FACS) analysis as detailed in the Materials and Methods section. The results are representative of at least two independent experiments); (B) The sensitivity of various CD19+ NHL lines (Ramos, Raji, Daudi) to CD19CAR CTL killing; (C) CD19CAR CTLs kill NHL cells in a CD19-specific, and caspase- and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated manner. Ramos NHL cells were left either untreated or pretreated with TRAIL, CD19 blocking mAb or zVAD-fmk (1.0 μg/mL, 6 h) and were used in a 51Cr-release assay using CD19CAR CTLs as effectors. BCBL-1 NHL cells were used as a negative control; (D) The specificity of CD19CAR Jurkat killing of NHL. The killing of NHL cells by CD19CAR transduced Jurkat cells (sorted to 100% purity) was significantly reduced by pretreatment of the cells with anti-CD19 mAb (1 μg/mL, 6 h). (E) Killing of the CD19 negative NHL B-cell line, BCBL-1, by various immune effector cells. * p values < 0.05 are considered to be significant.